Form 4: 10X Fund Reduces Galectin Therapeutics Stake

10X Fund, a 10% owner of Galectin Therapeutics Inc., sold 150,000 shares of common stock in early December 2025.

Summary

• 10X Fund, L.P., a 10% owner and related party to Galectin Therapeutics Inc. (GALT), reported sales of common stock.
• On December 2, 2025, 10X Fund, L.P. disposed of 30,000 shares of common stock at a weighted average price of $5.47 per share.
• Following the December 2nd transaction, 10X Fund, L.P. directly beneficially owned 5,802,207 shares.
• On December 3, 2025, an additional 120,000 shares of common stock were sold at a weighted average price of $5.73 per share.
• After both transactions, 10X Fund, L.P. directly beneficially owned 5,682,207 shares of common stock.
• The sales were made pursuant to a Rule 10b5-1(c) plan.
• James C. Czirr, as Managing Member of 10X Capital Management, LLC (general partner of 10X Fund, L.P.), and individually, may be deemed to have indirect beneficial ownership but disclaims ownership except to the extent of pecuniary interest.

Sentiment

Score: 3

Explanation: The sentiment is negative due to a significant insider sale by a 10% owner, which typically signals reduced confidence or a strategic exit, potentially impacting investor perception negatively.

Positives

• NA

Negatives

• A 10% owner, 10X Fund, L.P., sold a total of 150,000 shares of common stock over two days, which could be interpreted as a reduction in confidence or a need for liquidity by a significant insider.
• The sales occurred at weighted average prices of $5.47 and $5.73, potentially indicating that the insider found these price levels attractive for divestment.

Risks

• NA

Future Outlook

NA

Management Comments

• James C. Czirr signed the filing as Managing Member of the General Partner for 10X Fund, LP, as Managing Member of 10X Capital Management, LLC, and individually.

Industry Context

NA

Related Party Transactions

• 10X Fund, L.P., a 10% owner of Galectin Therapeutics Inc., sold 150,000 shares of common stock. This constitutes a related party transaction as it involves a significant shareholder and director-affiliated entity.

Stakeholder Impact

• Shareholders may view the significant insider selling by a 10% owner as a negative signal regarding the company's near-term prospects or valuation, potentially leading to decreased investor confidence and downward pressure on the stock price.

Key Dates

Recommendation

The significant sale of 150,000 shares by a 10% owner, 10X Fund, L.P., warrants a 'Hold' recommendation with caution. While not a complete divestment, such insider selling by a major shareholder can signal a lack of confidence or a strategic shift, which could negatively impact market sentiment. Investors should monitor future insider activity and company developments closely before making further investment decisions.

Keywords

GALT, Galectin Therapeutics, 10X Fund, Insider Sale, Form 4, Beneficial Ownership, Stock Transaction, Rule 10b5-1